ASCO: Gilead's Trodelvy limps forward in new breast cancer lane as below-par showing casts doubt

After Gilead Sciences dropped an ambiguous line for Trodelvy’s performance in HR-positive, HER2-negative breast cancer in March, all eyes are on this weekend's data presentation. And those detailed results don’t exactly meet doctors’ expectations.